Amcil Limited Overview
AMCIL Limited is a small, internally administered Australian listed investment company that runs a deliberately concentrated, benchmark-unaware portfolio of roughly 30–45 high-quality Australian and New Zealand listed companies, spanning mega-caps such as Macquarie Group, BHP and CSL alongside founder-led small and mid-caps such as ARB Corporation, Netwealth and Temple & Webster. It sits within the AFIC family of four LICs serviced at cost by Australian Investment Company Services, which gives it institutional research depth and a sub-0.6% management expense ratio with no performance fees despite a portfolio of only ~A$340 million. Its stated objectives are medium-to-long-term capital growth and fully franked dividends, supplemented by special dividends funded from realised gains. AMCIL's distinctive feature — equal emphasis on small and large companies in a focused book — produced strong outperformance in FY2024 but severe underperformance in FY2025–FY2026, leaving the shares at a persistent mid-teens discount to NTA as a new CEO takes charge.
What the company does
AMCIL is a closed-end listed investment company. It raises permanent equity capital from shareholders, invests that capital in listed equities, and returns value to shareholders through (i) growth in net asset backing per share and (ii) fully franked dividends funded from the dividend income it receives plus, periodically, realised capital gains. Because it is closed-ended, it is never forced to sell assets to meet redemptions, which is the core structural advantage LIC managers emphasise over open-ended managed funds.
Company's own description (paraphrased from AR FY2026). AMCIL describes itself as managing a focused portfolio covering large and small companies in the Australian and New Zealand equity markets. Its investment objectives are attractive returns through strong capital growth in the portfolio over the medium to long term, together with the generation of fully franked dividends. The investment philosophy centres on "quality first", followed by growth and value: it prefers companies with leadership positions in their industries and durable competitive advantages, long-term sustainable business models with low disruption risk, limited exposure to adverse regulatory influences, outstanding management and boards aligned with shareholders, stable income flows and strong, self-funding balance sheets. It evaluates metrics such as return on capital employed, return on equity, gearing, margins and free cash flow, and it votes on every resolution at investee companies, publishing its voting record.
Independent characterisation. AMCIL is best understood as a high-conviction, quality-growth Australian equity strategy wrapped in a tax-efficient corporate structure. Relative to its larger sibling AFIC (a diversified, income-oriented, ~A$9.8 billion portfolio), AMCIL is the group's "concentrated, all-cap" vehicle: its top 20 holdings were 72.6% of the portfolio at 30 June 2026, and small companies are permitted to carry position sizes that matter. The strategy has historically leaned heavily toward healthcare, technology and "owner-driver" businesses and away from banks and resources, which made it highly sensitive to the FY2026 market rotation into Materials (+52.1%) and out of Healthcare (−36.2%) and Information Technology (−37.0%), as reported in AR FY2026.
Business model and revenue model
| Revenue / value stream | Nature | FY2026 amount (AUD K) | Share of income from operating activities | Source |
|---|---|---|---|---|
| Dividends and distributions from portfolio companies | Recurring investment income; largely franked | 8,452 | 86.2% | AR FY2026 Income Statement |
| Interest on cash deposits (Commonwealth Bank) | Recurring, rate-sensitive | 818 | 8.3% | AR FY2026 |
| Income from options written portfolio | Call options written over holdings; opportunistic premium income | 530 | 5.4% | AR FY2026 |
| Net gains on trading portfolio | Small short-term trading book; nil in FY2026 | 0 | 0.0% | AR FY2026 |
| Income from operating activities | — | 9,800 | 100% | AR FY2026 |
| Realised capital gains (pre-tax, through OCI, not profit) | Funds special dividends and "LIC capital gain" attributable amounts | 8,780 | n/a (capital account) | AR FY2026 Statement of Comprehensive Income |
There is no product, service, subscription or licensing revenue. The "revenue mix" of an LIC is a mix of investment income types. Shareholder value creation is dominated by the capital account (FY2026 unrealised losses of A$59.6 million pre-tax dwarfed operating profit of A$6.9 million), so reported "profit" is a poor guide to economic performance; the relevant measure is total portfolio return (net asset growth plus dividends including franking), which was −10.0% in FY2026.
Value-chain position, customers and end-markets
Value-chain position: Capital allocator / end-investor in listed equities. AMCIL sits downstream of the stock exchange and upstream of retail shareholders; it does not intermediate client money in the way an asset manager does.
Customer types (shareholders): Predominantly Australian retail investors, self-managed super funds (SMSFs), family offices and private foundations. At 20 July 2026 there were 2,864 holdings; the 20 largest holders owned 35.19% and the Teele family entities collectively held ~17% (AR FY2026). Holdings of 100,000+ shares accounted for 81.95% of capital.
End-markets (where capital is deployed): Australian and New Zealand listed equities across Healthcare (15.6% of portfolio), Other Financials & Real Estate (22.2%), Industrials (14.6%), Information Technology (10.4%), Telecommunications/Communication Services (9.3%), Materials (8.6%), Consumer Discretionary (7.2%), Consumer Staples (3.6%), Energy (3.4%), Banks (0.0%) and Cash (5.0%) at 30 June 2026 (AR FY2026 Note B3).
Cost model: AMCIL pays AICS an administration fee (A$1.181 million in FY2026) covering investment management, financial reporting and key personnel, plus its own "other administration expenses" (A$0.930 million, of which directors' fees were A$0.435 million). There is no base management fee linked to funds under management in the conventional external-manager sense and no performance fee (FNN interview, FY2025 results).
Strategy
Stated strategy (themes from AR FY2026 and FY2026 results webcast)
-
Quality first, then growth, then value. Six quality criteria (industry leadership, sustainable low-disruption model, regulatory resilience, aligned management and governance, stable income, financial strength) remain unchanged from AR FY2024 to AR FY2026.
-
Focused, high-conviction portfolio of 30–40 companies, large and small. The FY2026 webcast reiterated a high-conviction book of 30 to 40 high-quality companies. Late in FY2026 management actively reduced the number of holdings to concentrate capital where long-term conviction is highest relative to risk.
-
Long-term, tax-aware ownership with low turnover — although turnover rose to ~27% in FY2026 during the restructuring.
-
Fully franked dividends supplemented by specials from realised gains, with LIC capital gain attributable amounts passed through to shareholders.
-
Low cost, internally administered model — no performance fees; MER 0.57%.
-
Discount management — enhanced broker and financial-planner communication, weekly NTA disclosure and orderly on-market buy-backs.
-
Responsible ownership — voting on all resolutions, engagement on governance, consideration of climate and social risks; portfolio carbon intensity assessed (using ISS ESG data) as below the S&P/ASX 200.
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Detail | Target / metric | Source |
|---|---|---|---|---|
| Bank exit programme | FY2025–FY2026 | Exited CBA (FY2025), then Westpac and NAB (FY2026); banks 0% of portfolio | Valuation discipline | AR FY2026; FNN FY2025 |
| Technology de-risking | FY2026 | Exited REA Group and WiseTech Global; reduced IT from 15.3% to 10.4% | Reduce concentration and AI-disruption risk | AR FY2026 |
| Small-cap pruning | FY2026 | Exited EQT Holdings, ReadyTech, Beamtree, Redox, The Environmental Group, IDP Education | Higher conviction | AR FY2026 |
| Contrarian turnaround additions | FY2026 | Initiated Ramsay Health Care, ASX Ltd (new management), AUB Group (de-rated), Nanosonics; added to SEEK, Sigma, Woodside | Value entry into quality franchises | AR FY2026 |
| On-market buy-back | FY2025–FY2026 (plan announced 22 Jan 2026) | 3.9m shares (A$4.3m) in FY2025; 7.5m shares (A$7.6m, avg A$1.01) in FY2026 | Accretive at ~16% discount | AR FY2026 |
| Weekly NTA disclosure | FY2026 | Estimated pre-tax NTA released weekly | Discount narrowing | AR FY2026 |
| Mandate broadening language | FY2025 | Description changed to "Australian and New Zealand" equity markets | — | AR FY2025/FY2026 |
| CEO succession | Feb–Jul 2026 | Gibson succeeds Freeman across all four AICS LICs | Leadership continuity | AFIC announcement 17 Feb 2026 |
| Cash reserve for dislocations | FY2026 | Cash ~5% of portfolio retained for market dislocations | Opportunistic deployment | AR FY2026 Outlook |
Guidance and medium-term targets
AMCIL does not provide earnings guidance or medium-term financial targets; the Directors state explicitly that they do not believe it possible or appropriate to forecast markets or investment results (AR FY2026, Likely Developments). Implicit benchmarks are the S&P/ASX 200 Accumulation Index (including franking) over 1/3/5/10 years and the MER trend. No cost programme with a quantified target has been announced.
Products & Services
Products offered to investors
| "Product" / service | Description | Target customer | Pricing / terms | Source |
|---|---|---|---|---|
| AMH ordinary shares | Single class of fully paid ordinary shares; one vote per share on a poll | Retail, SMSF, family offices | Market price on ASX; currently at ~16% discount to pre-tax NTA | AR FY2026 |
| Dividend Reinvestment Plan (DRP) | Dividends reinvested in new shares priced at the 5-day average selling price after ex-date; no discount | Existing holders | 0% discount (FY2026 dividend notice) | AR FY2026 Note D6; dividend notice 28 Jul 2026 |
| Dividend Substitution Share Plan (DSSP) | Holders forgo the dividend and receive shares instead (tax-deferral feature) | Higher-tax-rate holders | Priced as per DRP | AR FY2026 Note D6 |
| LIC capital gain attributable part | Tax-deduction entitlement attached to dividends paid from realised long-term gains; 2.14c per share attached to FY2026 final + special | Eligible taxpayers | Embedded in dividend | AR FY2026 |
| Weekly estimated NTA and monthly NTA/top-20 reports | Transparency tools introduced/expanded partly to address the discount | All investors | Free (ASX releases, website) | AR FY2026 Share Price section |
| Shareholder webcasts and AGM (hybrid) | Half-year and full-year results webcasts; hybrid AGMs | All investors | Free | FY2026 Appendix 4E |
Investment portfolio — complete holdings register at 30 June 2026 (the operating "catalog")
| Code | Company | Activity (summarised) | Shares held FY2025 (000) | Shares held FY2026 (000) | Market value FY2026 (AUD K) | % of portfolio |
|---|---|---|---|---|---|---|
| MQG | Macquarie Group | Diversified financial services | 103 | 96 | 24,103 | 7.5 |
| BHP | BHP | Diversified resources | 442 | 382 | 22,682 | 7.0 |
| TCL | Transurban Group | Toll roads | 1,226 | 1,226 | 17,630 | 5.5 |
| GMG | Goodman Group | Industrial property | 546 | 446 | 13,884 | 4.3 |
| MFT | Mainfreight (NZX) | Freight and logistics | 249 | 249 | 12,687 | 3.9 |
| CSL | CSL | Biopharmaceuticals | 121 | 110 | 12,644 | 3.9 |
| WOW | Woolworths Group | Supermarkets | 228 | 308 | 12,329 | 3.8 |
| CAR | CAR Group | Online auto classifieds | 397 | 453 | 11,669 | 3.6 |
| WDS | Woodside Energy | Oil and gas | 230 | 412 | 11,623 | 3.6 |
| RMD | ResMed | Sleep/respiratory devices | 337 | 347 | 10,007 | 3.1 |
| SIG | Sigma Healthcare | Pharmacy (Chemist Warehouse) | 2,054 | 3,524 | 9,691 | 3.0 |
| TLS | Telstra Group | Telecommunications | 1,538 | 1,880 | 9,550 | 3.0 |
| MAQ | Macquarie Technology Group | Data centres, telco | 200 | 134 | 9,391 | 2.9 |
| RHC | Ramsay Health Care | Private hospitals | 0 | 195 | 8,554 | 2.7 |
| ALQ | ALS | Testing laboratories | 550 | 365 | 8,337 | 2.6 |
| WES | Wesfarmers | Diversified retail/industrial | 123 | 91 | 8,235 | 2.6 |
| XYZ | Block Inc | Fintech / payments | 56 | 72 | 8,235 | 2.6 |
| ARB | ARB Corporation | 4WD accessories | 384 | 403 | 7,623 | 2.4 |
| RGN | Region Group | Shopping centre REIT | 3,250 | 3,250 | 7,573 | 2.3 |
| AIA | Auckland International Airport | Airport | 780 | 1,075 | 7,489 | 2.3 |
| FPH | Fisher & Paykel Healthcare | Respiratory devices | 230 | 230 | 7,372 | 2.3 |
| NWL | Netwealth Group | Investment platform | 343 | 329 | 6,764 | 2.1 |
| AUB | AUB Group | Insurance broking | 0 | 229 | 6,568 | 2.0 |
| NXT | NEXTDC | Data centres | 309 | 440 | 6,420 | 2.0 |
| TNE | Technology One | Enterprise software | 168 | 214 | 6,308 | 2.0 |
| ASX | ASX Ltd | Securities exchange | 0 | 107 | 5,679 | 1.8 |
| BRG | Breville Group | Small appliances | 141 | 169 | 5,449 | 1.7 |
| SEK | SEEK | Employment classifieds | 65 | 398 | 5,353 | 1.7 |
| EVT | EVT | Cinemas, hotels | 310 | 391 | 5,030 | 1.6 |
| OCL | Objective Corp | Government software | 348 | 433 | 4,465 | 1.4 |
| 360 | Life360 | Family location app | 137 | 141 | 3,754 | 1.2 |
| JHX | James Hardie Industries | Fibre cement | 246 | 94 | 3,586 | 1.1 |
| REH | Reece | Plumbing distribution | 240 | 196 | 3,377 | 1.0 |
| TPW | Temple & Webster | Online furniture | 220 | 492 | 3,052 | 0.9 |
| COH | Cochlear | Hearing implants | 24 | 24 | 2,885 | 0.9 |
| AMC | Amcor | Packaging | 526 | 46 | 2,878 | 0.9 |
| XRO | Xero | Cloud accounting | 27 | 39 | 2,806 | 0.9 |
| GTK | Gentrack Group | Utility billing software | 715 | 687 | 2,170 | 0.7 |
| NAN | Nanosonics | Infection control | 0 | 570 | 1,898 | 0.6 |
| HUB | HUB24 | Investment platform | 42 | 22 | 1,614 | 0.5 |
| PXA | PEXA Group | Digital property settlement | 0 | 100 | 1,030 | 0.3 |
| — | Total | — | — | — | 322,394 | 100.0 |
All 41 listed holdings disclosed in AR FY2026 "Holdings of Securities", with 2025 and 2026 share counts and 2026 market values.
Notes: (1) AMCIL also holds an unlisted Level 3 investment in Marketplacer (software), disclosed in Note A2; it carried A$487k in AR FY2024 and does not appear as a separate line in the FY2026 holdings table, implying an immaterial or nil carrying value (not separately disclosed). (2) PEXA's FY2025 count is shown as zero in AR FY2026 although AMCIL held 209k shares at 30 June 2024; this implies an exit in FY2025 and re-entry in FY2026.
Top-20 concentration trend
| Concentration metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Top 20 as % of portfolio (excl. cash) | 74.8 | — | 72.6 |
| Largest single holding % | 9.1 | 7.4 | 7.5 |
| Number of holdings over 5% | 4 | 2 | 3 |
| Number of listed holdings at 30 June | 44 | — | 41 |
Sources: AR FY2024; AR FY2026. FY2024 largest holding was CSL (9.1%); FY2025 CSL (7.4%); FY2026 Macquarie Group (7.5%).
Financial Narrative
Basis. FY2023–FY2026 statutory figures are from AR FY2024 and AR FY2026 (which contain FY2023 and FY2025 comparatives). FY2022 figures come from the 5-Year Summary in AR FY2026, the opening balances in AR FY2024's Statement of Changes in Equity and Cash Flow Statement, and — where flagged — the aggregator Stoxray (FY2022 operating income A$9.306m and operating cash flow A$6.321m). For an LIC with no depreciation or amortisation, "operating income" is defined here as profit before finance costs and tax, and EBITDA equals operating income. "Revenue" is "income from operating activities".
Income statement (A$000 unless stated)
Gross profit is not a meaningful concept for an LIC (there is no cost of goods sold); gross margin is therefore not presented. Diluted EPS equals basic EPS because there are no options or convertibles on issue (AR FY2026 Note A5). FY2022 EPS is the rounded 5-Year Summary figure. FY2022 MER (0.52%) is from the AR FY2023 "Year in Summary" comparative.
Margins and growth (%)
CAGRs (FY2022→FY2026, four years): income from operating activities +1.3% p.a. (A$9.306m → A$9.800m, FY2022 aggregator base); NPAT −3.9% p.a. (A$8.115m → A$6.920m); pre-tax NTA per share +1.2% p.a. (A$1.03 → A$1.08); ordinary dividend flat at 3.5c. The low effective tax rate reflects franking-credit offsets on franked dividends received (A$1.37m offset in FY2026, Note B2).
Commentary. Profit has trended down since the FY2022 peak because AMCIL has steadily rotated away from high-yield stocks (banks, BHP, Wesfarmers) toward lower-yielding growth and quality names, and because the portfolio itself shrank in FY2026. FY2026 bucked the trend modestly (+3.6%) thanks to higher interest income (A$818k vs A$537k), a recovery in options premium (A$530k vs A$357k) and a 9% cut in administration costs (A$2.111m vs A$2.314m), principally lower AICS fees. Margins are structurally high and stable (70–80%) because the cost base is small and largely fixed; the FY2025 dip reflects a one-year rise in AICS fees.
Balance sheet (A$000 at 30 June)
FY2022 cash, equity, reserves and share count are the 1 July 2022 opening balances in AR FY2024; FY2022 investments and NTA from the 5-Year Summary (AR FY2026). AMCIL has a A$10 million cash advance facility with Commonwealth Bank, undrawn at every year-end reviewed and now expiring 30 June 2028 (AR FY2026 Note D2); AR FY2024 notes the facility was utilised intra-year in FY2024.
Commentary. The balance sheet is ungeared and highly liquid: 95% of assets are Level 1 listed equities and the remainder is cash. Equity fell A$49.8 million in FY2026 (−13.7%) through a combination of A$35.8 million of net-of-tax investment losses, A$20.2 million of dividends paid (inflated by the 3.0c FY2025 special) and A$0.7 million net capital reduction (A$7.6 million buy-backs exceeding A$7.0 million of DRP issuance). The deferred tax liability on unrealised gains roughly halved to A$25.4 million, which is why the gap between pre- and post-tax NTA narrowed from 14c to 9c. The realised capital gains reserve (A$25.0 million) and the LIC capital gain account (A$7.6 million attributable gain, of which A$6.7 million is being distributed with the FY2026 final and special dividends) are the reservoirs for future special dividends.
Cash flow (A$000)
Commentary. Operating cash flow covers the ordinary dividend (3.5c × ~315m shares ≈ A$11 million) only about 0.6×; the gap is closed by realised gains, DRP reinvestment and the run-down of retained profits. This is normal for a total-return LIC that pays a "profit + realised gains" distribution, but it means ordinary dividend sustainability depends on the portfolio continuing to generate both franked income and taxable gains. Portfolio turnover (sales ÷ average portfolio) rose from roughly 15% in FY2023 to 18% in FY2024, 20% in FY2025 and 27% in FY2026, a notable increase for a self-described "low turnover, tax-aware" investor and a sign of the late-FY2026 portfolio restructuring. Brokerage paid rose to A$474k in FY2026 (416 transactions) from A$325k in FY2024 (354 transactions).
Ratios
Cash conversion cycle: not applicable (no inventories, trade receivables are settlement-cycle only, no trade payables of substance).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Portfolio Details
| Portfolio | Purpose | Accounting treatment | Size at 30 Jun 2026 |
|---|---|---|---|
Investment portfolio | Long-term holdings | Fair value through other comprehensive income (OCI); gains/losses never recycled to profit | A$322.4 million |
Options written portfolio | Call (and occasionally put) options written over investment holdings to earn premium | Fair value through profit or loss | Nil open at 30 June 2026 (A$73k liability at 30 June 2025) |
Trading portfolio | Small short-term positions | Fair value through profit or loss | Nil |
Income stream (AUD K)
| Income stream (AUD K) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Dividends and distributions | 9,371 | 9,231 | 8,602 | 8,452 |
Interest on deposits | 401 | 293 | 537 | 818 |
Other income | 0 | 5 | 0 | 0 |
Net gains on trading portfolio | -6 | 209 | 86 | 0 |
Income from options written portfolio | 578 | 391 | 357 | 530 |
Income from operating activities (total) | 10,344 | 10,129 | 9,582 | 9,800 |
Revenue by Segment (%) and Segment Margins & Growth (%)
| Derived metric (%) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Dividends as % of operating income | 90.6 | 91.1 | 89.8 | 86.2 |
Interest as % of operating income | 3.9 | 2.9 | 5.6 | 8.3 |
Options + trading as % of operating income | 5.5 | 6.0 | 4.6 | 5.4 |
YoY growth in operating income | — | -2.1 | -5.4 | 2.3 |
Pre-tax profit margin on operating income | 77.4 | 78.5 | 74.9 | 77.5 |
Revenue by Segment (%)
| Sector (%) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Energy | 2.55 | 1.52 | 1.32 | 3.43 |
Materials | 9.62 | 7.83 | 8.27 | 8.59 |
Industrials | 14.75 | 14.36 | 13.66 | 14.60 |
Consumer Discretionary | 12.38 | 13.00 | 8.12 | 7.18 |
Consumer Staples | 3.14 | 1.94 | 1.73 | 3.63 |
Banks | 8.09 | 7.08 | 2.95 | 0.00 |
Other Financials and Real Estate | 16.92 | 18.12 | 19.39 | 22.23 |
Telecommunications | 12.00 | 7.86 | 9.14 | 9.31 |
Healthcare | 16.06 | 14.76 | 15.78 | 15.64 |
Information Technology | 3.05 | 10.53 | 15.25 | 10.41 |
Cash | 1.44 | 3.00 | 4.39 | 4.98 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Income from operating activities (AUD K; FY2022 aggregator) | 9,306 | 10,344 | 10,129 | 9,582 | 9,800 |
Total revenue — dividends, interest, other (AUD K) | — | 9,772 | 9,529 | 9,139 | 9,270 |
Administration expenses (AUD K) | — | 2,242 | 2,061 | 2,314 | 2,111 |
of which AICS administration fee (AUD K) | — | 1,216 | 1,011 | 1,343 | 1,181 |
Operating income = EBITDA (AUD K) | — | 8,102 | 8,068 | 7,268 | 7,689 |
Finance costs (AUD K) | — | 91 | 113 | 90 | 92 |
Profit before tax (AUD K) | — | 8,011 | 7,955 | 7,178 | 7,597 |
Income tax expense (AUD K) | — | 456 | 477 | 499 | 677 |
Net profit after tax (AUD K) | 8,115 | 7,555 | 7,478 | 6,679 | 6,920 |
Basic EPS (A$ cents) | 2.7 | 2.43 | 2.38 | 2.11 | 2.19 |
Diluted EPS (A$ cents) | 2.7 | 2.43 | 2.38 | 2.11 | 2.19 |
Dividends declared per share (A$ cents, incl. special) | 3.5 | 5.0 | 4.0 | 6.5 | 4.0 |
of which special dividend (A$ cents) | 0 | 1.5 | 0.5 | 3.0 | 0.5 |
Total comprehensive income (AUD K) | — | 27,937 | 47,161 | 20,011 | -28,891 |
Management expense ratio (%) | 0.52 | 0.66 | 0.56 | 0.56 | 0.57 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
EBITDA / operating margin (%) | — | 78.3 | 79.7 | 75.9 | 78.5 |
Pre-tax margin (%) | — | 77.4 | 78.5 | 74.9 | 77.5 |
Net margin (%) | 87.2 | 73.0 | 73.8 | 69.7 | 70.6 |
Effective tax rate (%) | — | 5.7 | 6.0 | 7.0 | 8.9 |
Operating income growth YoY (%) | — | 11.2 | -2.1 | -5.4 | 2.3 |
NPAT growth YoY (%) | — | -6.9 | -1.0 | -10.7 | 3.6 |
Balance Sheet and Share Count (millions)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and equivalents (AUD K) | 21,714 | 4,954 | 11,946 | 18,042 | 16,890 |
Investment portfolio at market value (AUD K) | 306,600 | 341,359 | 386,196 | 392,695 | 322,394 |
Total assets (AUD K) | — | 348,485 | 399,498 | 412,018 | 340,617 |
Total debt — short term (AUD K) | 0 | 0 | 0 | 0 | 0 |
Total debt — long term (AUD K) | 0 | 0 | 0 | 0 | 0 |
Net debt (negative = net cash) (AUD K) | -21,714 | -4,954 | -11,946 | -18,042 | -16,890 |
Deferred tax liability on investment portfolio (AUD K) | 17,860 | 27,597 | 43,229 | 43,093 | 25,382 |
Total liabilities (AUD K) | — | 28,284 | 44,267 | 49,391 | 27,809 |
Shareholders' equity (AUD K) | 300,970 | 320,201 | 355,231 | 362,627 | 312,808 |
Share capital (AUD K) | 221,801 | 223,819 | 227,101 | 226,910 | 226,204 |
Revaluation reserve (AUD K) | 27,337 | 48,181 | 82,385 | 82,007 | 40,100 |
Realised capital gains reserve (AUD K) | 37,266 | 26,080 | 19,240 | 32,950 | 25,038 |
Retained profits (AUD K) | 14,566 | 22,121 | 26,505 | 20,760 | 21,466 |
Goodwill and intangibles (AUD K) | 0 | 0 | 0 | 0 | 0 |
Working capital (AUD K) | — | 5,653 | 12,366 | 13,116 | 15,895 |
Shares on issue (millions) | 309.9 | 311.9 | 315.4 | 315.4 | 314.5 |
NTA per share pre-tax (AUD) | 1.03 | 1.12 | 1.26 | 1.29 | 1.08 |
NTA per share post-tax (AUD) | — | 1.03 | 1.13 | 1.15 | 0.99 |
Cash Flow and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD K; FY2022 aggregator) | 6,321 | 7,660 | 7,036 | 6,474 | 6,326 |
Capital expenditure (AUD K) | 0 | 0 | 0 | 0 | 0 |
Free cash flow (AUD K) | 6,321 | 7,660 | 7,036 | 6,474 | 6,326 |
Sales from investment portfolio (AUD K) | — | 47,796 | 66,799 | 76,216 | 96,817 |
Purchases for investment portfolio (AUD K) | — | 53,302 | 54,712 | 63,281 | 77,258 |
Tax paid on capital gains (AUD K) | — | 10,208 | 0 | 698 | 6,109 |
Dividends paid (AUD K) | — | 10,724 | 15,413 | 12,424 | 20,222 |
Shares issued under DRP (AUD K) | — | 2,029 | 3,299 | 4,147 | 6,961 |
Share buy-backs (AUD K) | — | 0 | 0 | 4,305 | 7,616 |
Net change in cash (AUD K) | — | -16,760 | 6,992 | 6,096 | -1,152 |
Dividends paid / operating cash flow (%) | — | 140 | 219 | 192 | 320 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE — NPAT / closing equity (%) | 2.70 | 2.36 | 2.11 | 1.84 | 2.21 |
Comprehensive ROE — total comprehensive income / closing equity (%) | — | 8.72 | 13.28 | 5.52 | -9.24 |
ROA — NPAT / closing total assets (%) | — | 2.17 | 1.87 | 1.62 | 2.03 |
ROIC — operating income / (equity + debt − cash) (%) | — | 2.57 | 2.35 | 2.10 | 2.59 |
Current ratio (x) | — | 9.23 | 14.21 | 3.11 | 7.83 |
Debt / equity (x) | 0 | 0 | 0 | 0 | 0 |
Net debt / EBITDA (x) | — | -0.61 | -1.48 | -2.48 | -2.20 |
Interest coverage — EBIT / finance costs (x) | — | 89.0 | 71.4 | 80.8 | 83.6 |
Asset turnover — operating income / total assets (%) | — | 2.97 | 2.54 | 2.33 | 2.88 |
Dividend payout — DPS declared / EPS (%) | 130 | 206 | 168 | 308 | 183 |
Portfolio turnover — sales / average portfolio (%) | — | 14.8 | 18.4 | 19.6 | 27.1 |
Revenue by Region
| Exposure by issuer domicile (AUD K) | FY2024 | FY2026 |
|---|---|---|
New Zealand-domiciled (Mainfreight, Auckland Airport, Fisher & Paykel, Gentrack, Xero) | 37,913 | 32,524 |
Offshore-domiciled, ASX-listed (ResMed, Block, Life360, James Hardie) | 22,209 | 25,582 |
Australian-domiciled | 325,913 | 264,288 |
Total investment portfolio | 386,035 | 322,394 |
Exposure share (%)
| Exposure share (%) | FY2024 | FY2026 |
|---|---|---|
New Zealand-domiciled | 9.8 | 10.1 |
Offshore-domiciled, ASX-listed | 5.8 | 7.9 |
Australian-domiciled | 84.4 | 82.0 |
Capital Markets Data and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price at 30 June (A$; FY2023–FY2025 implied from NTA and discount) | — | 1.01 | 1.10 | 1.08 | 0.90 |
Pre-tax NTA per share (AUD) | 1.03 | 1.12 | 1.26 | 1.29 | 1.08 |
Discount to pre-tax NTA (%) | — | 10.0 | 13.0 | 16.4 | 16.3 |
Market capitalisation at 30 June (AUD Mn; FY2023–FY2025 InvestSMART) | — | 313.4 | 346.9 | 339.1 | 283.1 |
Portfolio return incl. franking (%; FY2023 per AR FY2023 summary) | — | 13.5 | 20.5 | 6.4 | -10.0 |
S&P/ASX 200 Accumulation incl. franking (%) | — | — | 13.5 | 15.1 | 7.2 |
Total shareholder return incl. franking (%) | — | -2.1 | 17.5 | — | — |
Number of shareholders | 3,350 | 3,241 | 3,165 | 3,066 | 2,876 |
Share Price & Returns
| Horizon | Portfolio return incl. franking (% p.a.) | Index incl. franking (% p.a.) | Share price (price only) |
|---|---|---|---|
1 year | -10.0 | 7.2 | −16.3% (A$1.075 → A$0.90); TSR ≈ −10.2% before franking including 6.5c paid |
3 years | 4.9 | 11.9 | −10.5% cumulative (A$1.005 → A$0.90); TSR ≈ +5.0% cumulative before franking including 15.5c paid |
5 years | 2.3 | 9.2 | — |
10 years | 7.8 | 10.9 | — |
Valuation Multiples
| Multiple | AMCIL | Basis |
|---|---|---|
P/E (trailing) | 41.1x | EPS 2.19c |
Price / pre-tax NTA | 0.83x | NTA A$1.08 |
Price / post-tax NTA | 0.91x | NTA A$0.99 |
P/B (statutory book) | 0.91x | Equity A$312.8m ÷ 314.5m shares = A$0.995 |
EV / EBITDA | 34.6x | EV = A$283.1m − A$16.9m cash = A$266.2m; EBITDA A$7.69m |
EV / Sales | 27.2x | Operating income A$9.80m |
Dividend yield (FY2026 declared 4.0c) | 4.4% net; 6.3% grossed up | At A$0.90 |
Ordinary dividend yield (3.5c) | 3.9% net; 5.6% grossed up | At A$0.90 |
Dividend (A$ cents per share)
| Dividend (A$ cents per share) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Interim | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
Final | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 |
Special | 0 | 1.5 | 0.5 | 3.0 | 0.5 |
Total | 3.5 | 5.0 | 4.0 | 6.5 | 4.0 |
LIC capital gain attributable amount on final/special | 3.57 | 5.71 | 0 | 6.43 | 2.14 |
Franking (%) | 100 | 100 | 100 | 100 | 100 |
Analyst Conclusions
Management outlook
Management (AR FY2026, July 2026) views the Australian market as moderately expensive against long-term averages, expects sector valuation dispersion to drive volatility through the August 2026 reporting season, believes the portfolio's strong-balance-sheet holdings are positioned for earnings growth, and retains a healthy cash level for dislocations. No quantitative guidance is provided. Post-balance-date, pre-tax NTA recovered from A$1.04 (24 July) to A$1.09 ex-dividend at 31 August 2026.
Consensus
No sell-side consensus exists. Implied market expectations — embodied in a ~16–17% discount — are for continued relative underperformance or persistent structural discount.
Bull case
-
Discount capture plus buy-back accretion. At ~A$0.90 against ~A$1.09 NTA, investors buy the portfolio at ~83c in the dollar; the company itself repurchased 2.4% of capital in FY2026 at an average A$1.01, and continued buying at sub-A$0.95 is materially accretive.
-
Style mean reversion. The FY2026 loss was driven by sector rotation (Healthcare −36.2%, IT −37.0%) rather than balance-sheet failure; AMCIL has re-entered de-rated franchises (Ramsay, ASX, AUB, SEEK) at what management describes as attractive valuations, echoing the FY2024 rebound (+20.5%).
-
New leadership catalyst. A new CEO with a decade inside the AICS investment team and external HESTA experience can reset portfolio construction and discount-management policy without disrupting a 90-year group process.
Bear case
-
Track record erosion. AMCIL now lags its benchmark over 1, 3, 5 and 10 years (10-year 7.8% vs 10.9% p.a.), undermining the central rationale for a higher-cost concentrated vehicle.
-
Structural sub-scale. At ~A$340m, the MER (0.57%) is roughly four times that of AFIC and Argo, and the shrinking register (−14% holders since FY2022) suggests the discount may be structural rather than cyclical.
-
Income and dividend pressure. Dividend income has fallen three years running; EPS (2.19c) does not cover the 3.5c ordinary dividend, and the LIC gain account was largely distributed with the FY2026 final/special, limiting future specials unless gains are realised.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Weekly / monthly | Estimated NTA and discount trajectory; buy-back execution volumes |
| Oct 2026 onward | Any strategy statements from the new CEO following the 1 Oct 2026 AGM; AGM vote outcomes |
| Jan 2027 (scheduled 21 Jan 2027 per aggregators) | H1 FY2027 results: half-year return vs index, interim dividend, MER |
| Ongoing | Recovery of healthcare holdings (CSL, ResMed, Cochlear, Ramsay) and IT/classifieds (CAR, SEEK, TechnologyOne, Netwealth) |
| Ongoing | Any discount-control mechanisms (e.g., expanded buy-back, conditional tender offer, merger with a sister LIC) — none announced; speculative |
| Ongoing | Tax policy changes affecting franking or CGT for LIC shareholders |
| Jul 2027 | FY2027 results; whether special dividends continue |
Concluding analyst verdict
AMCIL is a well-governed, ungeared, low-cost (for its size) listed investment company whose investment process is sound but whose recent outcomes have been poor. The FY2026 result crystallises the tension: accounting profit rose 3.6% to A$6.9 million and administration costs fell 9%, yet the portfolio lost 10.0% against a 7.2% gain for the index, net assets fell 14%, and the shares remained stuck at a 16% discount to NTA. The underperformance was overwhelmingly a style event — a heavy healthcare and technology overweight and zero bank exposure colliding with a resources-led market and an AI-driven de-rating of software and classifieds — rather than evidence of capital impairment, and the portfolio's quality characteristics (strong balance sheets, leadership franchises) remain intact.
The investment case now rests on three variables. First, whether the concentrated quality-growth style recovers; AMCIL's FY2024 experience shows how quickly relative returns can swing when the regime turns. Second, whether the new CEO, Alison Gibson, treats the discount as a strategic problem rather than an uncontrollable market outcome; buy-backs at ~83c in the dollar are clearly accretive, but more decisive capital-management options exist within a four-LIC group sharing one manager. Third, whether the vehicle can justify its scale: a A$340 million portfolio with a 0.57% MER competing against sister vehicles at 0.14% is structurally challenged.
On balance, AMCIL screens as a deep-value, catalyst-dependent holding: the 17% discount and fully franked yield (~6.3% grossed up on FY2026 declarations) provide some margin of safety, but persistent long-horizon underperformance and sub-scale economics mean the discount may not close without either a performance turnaround or a corporate initiative. Monitoring priorities are the NTA discount, buy-back intensity, the first half under new leadership, and any strategic review of the group's LIC structure.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Committees | Background (summarised) | Education | Shares held 30 Jun 2026 |
|---|---|---|---|---|---|---|
Rupert Myer AO | Chairman, independent NED | Jan 2000 (Chair 2020) | Chair, Investment Committee | President, The Myer Foundation; Chairman, Yulgilbar Group; former Deputy Chairman Myer Holdings; former director Diversified United Investments, Healthscope | BCom (Hons) Melb, MA Cantab, FAICD | 2,424,016 |
Alison Gibson | Managing Director & CEO (from 13 Jul 2026); also MD of AICS, AFIC, DJW, MIR | Jul 2026 | Investment Committee | Portfolio Manager, Internal Australian Equities, HESTA; Portfolio Manager at the AICS LICs 2011–2021; earlier Executive Director, Goldman Sachs JBWere; 25+ years' experience | CFA, B Bus, Grad Dip App Fin, GAICD | Nil direct at 13 Jul 2026 (initial notice) |
Roger Brown | Independent NED | Feb 2014 | Investment Committee | NED of ARB Corporation; ARB Executive Chairman 1987–2016 and NE Chairman 2016–2022 | B.Eng, MBA | 2,260,015 |
Paula Dwyer | Independent NED | Jun 2023 | Audit and Investment Committees | Chair, Allianz Australia; NED TPG Telecom; former Chair Tabcorp, Healthscope, Blackmores; former NED ANZ (Audit Chair), Suncorp, Dexus Funds Management | BCom, FCA, SF Fin, FAICD | 110,868 |
Michael (Mike) Hirst | Independent NED | Jan 2019 | Chair, Audit Committee; Investment Committee | Chairman, AMP Limited; Director, Adelaide Airport, GMHBA; CEO Bendigo and Adelaide Bank 2009–2018 | B Com (Melb), SF Fin, FAICD | 284,304 |
Jon Webster AM | Independent NED | Nov 2016 | Audit and Investment Committees | Former Allens M&A partner (30+ years) and Allens board member; trustee R E Ross Trust; former member ASIC Audit and Risk Committee | BCom, LLB (Hons), LLM | 3,600,260 |
Mark Freeman | Managing Director (retired 30 Jun 2026) | CIO Feb 2007; CEO/MD Jan 2018 | Investment Committee | Former Partner, Goldman Sachs JBWere (12 years advising the LICs) | BE, MBA, Grad Dip App Fin, AMP (INSEAD), GAICD | 1,300,577 (at retirement) |
Executive Leadership Team
| Name | Title | Joined | Prior roles |
|---|---|---|---|
Alison Gibson | MD & CEO | Jul 2026 | HESTA; AICS 2011–2021; Goldman Sachs JBWere |
Andrew JB Porter OAM | CFO / Company Secretary | Jan 2005 | Regional COO, CSFB Corporate & Investment Banking; Andersen Consulting; Director of AUASB; former Chair of G100 |
Geoffrey N Driver | GM Business Development & Investor Relations | Jan 2003 | 18 years at National Australia Bank |
Matthew J Rowe | Company Secretary | Jul 2016 | Corporate governance adviser; UK funds-management company secretarial manager |
Kieran Kennedy, CFA | Portfolio Manager (AICS investment team; listed by Yahoo Finance as AMCIL Portfolio Manager; presented at Mirrabooka FY2026 webcast) | — | — |
“—” = not publicly disclosed.
Directors' Remuneration
| Director (AUD) | Fees FY2025 | Superannuation FY2025 | Total FY2025 | Fees FY2026 | Superannuation FY2026 | Total FY2026 |
|---|---|---|---|---|---|---|
R Myer (Chairman) | 130,045 | 14,955 | 145,000 | 129,464 | 15,536 | 145,000 |
R Brown | 65,022 | 7,478 | 72,500 | 64,732 | 7,768 | 72,500 |
P Dwyer | 65,022 | 7,478 | 72,500 | 72,500 | 0 | 72,500 |
M Hirst | 65,022 | 7,478 | 72,500 | 64,732 | 7,768 | 72,500 |
J Webster | 65,022 | 7,478 | 72,500 | 64,732 | 7,768 | 72,500 |
J Auster (retired Oct 2024) | 17,669 | 2,041 | 19,710 | — | — | — |
R M Freeman (MD) | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 407,802 | 46,908 | 454,710 | 396,160 | 38,840 | 435,000 |
Major Shareholders
| Rank | Holder | Shares | % |
|---|---|---|---|
| 1 | Teele Family Nominees Pty Ltd (Teele Family A/C) | 20,914,542 | 6.65 |
| 2 | Mr Bruce Ballantine Teele | 15,545,487 | 4.94 |
| 3 | Teele Family Foundation PL | 15,191,433 | 4.83 |
| 4 | Djerriwarrh Investments Limited | 11,235,686 | 3.57 |
| 5 | HSBC Custody Nominees (Australia) | 5,949,742 | 1.89 |
| 6 | Invia Custodian (Christine Joy Campbell A/C) | 4,996,270 | 1.59 |
| 7 | Invia Custodian (Terrence A Campbell A/C) | 4,910,542 | 1.56 |
| 8 | Ancona Valley Holdings (Roswell Super Fund) | 4,712,115 | 1.50 |
| 9 | R & J Webster (RJW Super Fund) — director-related | 3,600,260 | 1.14 |
| 10 | Teele Family Super Pty Ltd | 2,693,337 | 0.86 |
| 11 | Invia Custodian (Fobsha Pty Ltd A/C) | 2,608,693 | 0.83 |
| 12 | Netwealth Investments (Wrap Services) | 2,362,439 | 0.75 |
| 13 | Rogand Superannuation (Roger Brown-related) | 2,260,015 | 0.72 |
| 14 | Citicorp Nominees | 2,258,842 | 0.72 |
| 15 | BNP Paribas Noms (NZ) | 2,110,048 | 0.67 |
| 16 | FFSF Asset Management (FF Super Fund) | 2,050,000 | 0.65 |
| 17 | Chalcott Nominees (McGregor Family Super) | 1,831,945 | 0.58 |
| 18 | Gardiole Pty Ltd (RH Myer Super Fund) — director-related | 1,827,897 | 0.58 |
| 19 | Mrs Wai Ning Kenrick | 1,813,010 | 0.58 |
| 20 | Mr Ross Ernest Barker | 1,800,000 | 0.57 |
Competitive Landscape
Key Competitors
| Competitor | Type | Relative positioning vs AMCIL |
|---|---|---|
Australian Foundation Investment Company (AFI) | Internally managed LIC (sister) | Same manager, diversified large-cap income focus, ~A$9.8bn portfolio, MER 0.14%; dominant scale |
Argo Investments (ARG) | Internally managed LIC | ~A$8.2bn total assets, MER 0.14%, 86 holdings, outperformed in FY2026; moving to quarterly dividends |
Mirrabooka Investments (MIR) | Internally managed LIC (sister) | Mid/small-cap focus; A$635m portfolio; −10.8% FY2026 return; trades near NTA |
Djerriwarrh Investments (DJW) | Internally managed LIC (sister) | Enhanced-income strategy using options; cross-holder of AMCIL |
BKI Investment Company (BKI) | LIC | — |
Australian United Investment Co (AUI) | LIC | — |
Diversified United Investment (DUI) | LIC | — |
WAM Leaders (WLE) / WAM Capital (WAM) | Externally managed LICs (Wilson Asset Management) | — |
Whitefield Industrials (WHF) | LIC | — |
Broad-market Australian equity ETFs (e.g., Vanguard VAS, iShares IOZ, Betashares A200) | Index ETFs | — |
Peer Comparison FY2026
| Metric (FY2026) | AMCIL (AMH) | AFIC (AFI) | Argo (ARG) | Mirrabooka (MIR) |
|---|---|---|---|---|
Net profit (AUD Mn) | 6.9 | 293.5 | 260.2 | 13.0 |
Portfolio size (AUD Mn) | 339.3 | 9,800 | not disclosed here (total assets 8200) | 635.4 |
1-year portfolio return (%) | -10.0 | 0.9 | 8.7 | -10.8 |
Stated benchmark return (%) | 7.2 | 7.2 | 6.1 | 7.8 |
MER (%) | 0.57 | 0.14 | 0.14 | — |
Pre-tax NTA per share (AUD) | 1.08 | 7.93 | 10.84 | 2.82 |
Total dividends declared (A$ cents) | 4.0 | 31.5 | 38.5 | — |
Share price vs NTA | -16.3% (30 Jun) | — | discount acknowledged, not quantified | -1.1% (24 Jul) |



